Parkinsons Disease Biomarker Program (PDBP) Discovery Projects (U01) | Apply Online

Opportunity Summary:

The Parkinsons Disease Biomarker Program (PDBP) Discovery Projects (U01) funding opportunity (PAR 14 259) is a National Institutes of Health (NIH) cooperative agreement designed to accelerate the development of biological biomarkers for Parkinsons disease (PD) using human-derived data and specimens. The core goal is to fund projects for up to three years that move potential biomarkers through key early development steps, specifically discovery, assay optimization, and replication. The intent is not simply to generate interesting signals, but to push candidates far enough along the pipeline that they become more credible, standardized, and ready for broader use in research or, eventually, clinical contexts.

A defining feature of this FOA is that funded projects are expected to integrate with and strengthen the NINDS Parkinsons Disease Biomarker Program (PDBP). In practical terms, applicants are encouraged to align their study designs and data practices with the PDBP ecosystem so that the work contributes to a shared resource rather than remaining siloed. For the discovery or pilot phases, investigators may use biospecimens and data from the PDBP itself or from other existing (extant) collections. However, if non-PDBP specimens and data are used, the consent associated with those materials must allow for deposition of all resulting data into the PDBP Data Management Resource (DMR). This requirement signals that the program places a high value on data sharing, harmonization, and the long-term utility of the findings beyond a single lab or cohort.

While discovery can begin with PDBP or other extant resources, the FOA makes it clear that the replication stage is expected to rely on PDBP biospecimens and data. This emphasis on replication within a common program infrastructure addresses a frequent weakness in biomarker research: early findings that do not hold up when tested in an independent set of participants or when measured under more standardized conditions. By steering replication into the PDBP context, the program is effectively trying to increase reproducibility and comparability across studies, while also making sure that downstream users can understand exactly how a biomarker performed in a well-characterized PD resource.

The scope is strictly limited to human biomarkers. Animal studies or studies based on other disease models are explicitly described as not appropriate under this announcement. That boundary indicates the program is focused on translational relevance and near-term applicability to human PD, whether biomarkers are intended for diagnosis, disease stratification, progression tracking, or response to therapy, as long as the work is rooted in human samples and data.

Another major requirement is project management rigor. Applications must include a timeline with milestones, and milestones are not treated as window dressing. Annual milestones must provide clear indicators of progress and should be concrete enough to show whether the project is succeeding or encountering problems. These milestones are used in peer review to judge the strength and feasibility of the proposal, and they are also used after an award is made to evaluate whether the project should continue into non-competing years. In other words, continued funding is tied to demonstrated progress against predefined goals, consistent with the cooperative agreement structure that typically involves a higher level of programmatic involvement and active oversight than standard research grants.

From an administrative standpoint, the opportunity is categorized as discretionary funding using a cooperative agreement mechanism (U01) in the health activity area, under CFDA 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). The award ceiling listed is 490,000 (as provided in the opportunity summary). There is no cost sharing or matching requirement, which lowers the barrier for applicants who may not have the ability to commit non-federal funds.

Eligibility is broad and includes a wide range of organization types. Eligible applicants include for-profit organizations (including small businesses), nonprofit organizations (both 501(c)(3) and non-501(c)(3)), public and private institutions of higher education, and multiple levels of government (state, county, city or township, special district), along with public housing authorities/Indian housing authorities, independent school districts, and tribal governments and tribal organizations. The eligibility list also explicitly mentions various institution types and communities, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and Asian American Native American Pacific Islander serving institutions, as well as faith-based and community-based organizations. Notably, non-U.S. entities (foreign organizations) and regional organizations are also identified as eligible, along with U.S. territories or possessions and eligible agencies of the federal government, indicating the program is open to a wide range of applicants as long as they can meet the human biomarker focus and the PDBP integration and data deposition expectations.

Key dates indicate the FOA was posted and created on June 16, 2014, with an original and current closing date of May 4, 2016, and an archive date of June 4, 2016. The full announcement was hosted through the NIH grants guide (link provided in the source text), and contact support is routed through the NIH Office of Extramural Research (OER) webmaster emails for access or linking issues.

Overall, this grant opportunity is best understood as a structured, milestone-driven program aimed at producing robust, shareable, and replicable human PD biomarker evidence, tightly connected to the PDBP infrastructure. It prioritizes not only finding candidate biomarkers, but also improving assays and validating results in a common replication resource, while ensuring that resulting datasets are deposited into the PDBP DMR so the broader PD research community can build on the work.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Interventions for Health Promotion and Disease Prevention in Native American Populations (R01)

Previous opportunity: Multi Scale Program to Access Change in Acid Base Chemistry of Mtn Streams in MD, VA and WV

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 14 259

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 14 259) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 259", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.